← All trials
NCT06613178
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 2, 2024
- Primary completion
- Jul 1, 2027
- Completion date
- Dec 15, 2027
- First posted
- Sep 25, 2024
- Last posted
- Sep 25, 2024
- Enrollment
- 1100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- McGill UniversityLead sponsor
- University of British ColumbiaCollaborator
- University of MontrealCollaborator
- University of OttawaCollaborator
- Laval UniversityCollaborator
- University of ManitobaCollaborator
- Trillium Health PartnersCollaborator
- University of TorontoCollaborator
- McGill UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.